DIR fees

DIR fees (Direct and Indirect Remuneration) are the performance-based fees PBMs and Medicare Part D plan sponsors collect from network pharmacies, historically retroactive to the point of sale and tied to performance metrics like generic dispensing rate, adherence, and formulary compliance. The 2024 CMS Medicare Part D rule moved DIR collection to the point of sale, eliminating most retroactive clawback exposure for new claims while leaving substantial unresolved disputes on the pre-2024 claim book.

How DIR fees work

Historically, a pharmacy filling a Part D claim received reimbursement at one rate at the point of sale, then months later received a DIR clawback for a portion of that reimbursement based on performance metrics calculated retrospectively by the PBM or Part D plan. The metrics typically included generic dispensing rate, medication adherence (proportion of days covered), formulary compliance, and PDC-based quality scores. The clawback amount could be unpredictable and substantial, creating cash-flow uncertainty that destroyed many independent pharmacies in the 2017 to 2023 period.

The 2024 CMS final rule requires Medicare Part D DIR to be applied at the point of sale rather than retroactively. New claims after January 1, 2024 reimburse at the net rate. Pre-2024 claim disputes (clawbacks already taken or still pending) remain open under the prior framework, and the procedural mechanics for challenging them depend on the PBM's pharmacy services agreement and the Part D plan's grievance process.

When DIR fees apply

DIR fees apply to Medicare Part D claims. Commercial PBM contracts use parallel but distinct economic mechanisms (spread pricing, performance fees, network rebates) that are not "DIR" but operate on similar logic. Medicaid managed care PBM contracts vary by state. The 2024 rule applies to Medicare Part D only; commercial and Medicaid PBM economic terms remain governed by their contracts and applicable state law.

The pharmacy's exposure under DIR fees

Pre-2024 DIR clawbacks frequently ran 5 to 12 percent of point-of-sale reimbursement on Part D claims, with peak exposures higher for pharmacies with concentrated brand or specialty books. Post-2024, point-of-sale DIR means pharmacies see the final net rate immediately, which solves the cash-flow surprise problem but does not solve the underlying compression. Performance metrics calculations remain a defense angle on pre-2024 disputes, including disputes over the PBM's adherence calculation, the formulary compliance benchmark, and the application of pharmacy-network-wide averages to individual pharmacy performance.

Related terms

• MAC pricing The point-of-sale reimbursement ceiling that interacts with DIR fees to produce the net effective rate.
• Spread pricing The commercial PBM economic mechanic distinct from but parallel to Medicare Part D DIR fees.
• Recoupment The procedural mechanic by which DIR clawbacks were collected from pharmacy reimbursement.
• Provider manual The PBM document that sets the DIR performance metrics and the dispute process.

See also

• Practice area
  Recoupment Defense

  Defense framework for pre-2024 DIR clawback disputes and other PBM post-payment recoupment patterns.

• Practice area
  PBM Audit Defense

  The full PBM audit defense framework, including performance-metric disputes that escalate into formal audit posture.